Randomised trial of initial low-dose CCB and ARB combination in Chinese hypertension patients (updated in February 5 2009)

INTERVENTION: Group 5:(Total Cholesterol concentration of participants: <4.0 or >6.1mmol/L). Amlodipine 2.5mg and compound amiloride half of a tablet.;Group 6:(Total Cholesterol concentration of participants <4.0 or >6.1mmol/L). Amlodipine 2.5mg and telmisartan 40mg.;Group 3:(Total Cholesterol concentration of participants: 4.0‐6.1mmol/L). Amlodipine 2.5mg, telmisartan 40mg and simvastatin 10mg.;Group 4:(Total Cholesterol concentration of participants: 4.0‐6.1mmol/L). Amlodipine 2.5mg and telmisartan 40mg, regular remedy of serum lipid decided by the doctors.;Group 2:(Total Cholesterol concentration of participants 4.0‐6.1mmol/L). Amlodipine 2.5mg and compound amiloride half of a tabella and regular remedy of serum lipid decided by the doctors.;Group 1:(Total Cholesterol concentration of participants: 4.0‐6.1mmol/L). Amlodipine 2.5mg, compound amiloride 2.5mg and simvastatin 10mg;Group A:(Includes group 1, group 2, and group 5). Amlodipine 2.5mg, compound amiloride half of a tablet.;Group B:(Includes group 3, group 4 and group 6). Amlodipine 2.5mg, telmisartan 40mg.; CONDITION: Hypertension PRIMARY OUTCOME: Incidence rate of compound cardiovascular event; SECONDARY OUTCOME: Change of life style;Change of blood pressure;blood pressure control rate;Change of eye fundus;Quality of Life;Change of MMSE;Change of the knowlege of hypertention;Incidence of stroke;Incidence of diabetes;Incidence of atrial fibrillation; INCLUSION CRITERIA: 1. primary hypertension; 2. age 50 79 year; 3. with one or more risk factor on cardiovascular disease; 4. able to sign the informed consent form